In the prognostic analysis of progression-free interval (PFI), CYP4B1 (p = 6.40e-05) and KRT6A (p = 0.0111) had the highest impact on PFI in patients with lung adenocarcinoma, and FAM83A had a higher impact on PFI in KIRC (p = 0.0002052). This evidence concerns the gene CYP4B1 and lung adenocarcinoma.